Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
Increasingly, IO researchers and biotech R&D teams are prioritising localised IL-12 delivery mechanisms that target tumours directly. We are currently selecting our lead IL-18 variant on the basis of potency for the IL-18 receptor, optimal pharmacokinetic profile and in vivo efficacy for inhibiting tumour growth.
98 
Let's personalize your content